Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects.
Monoclonal antibody therapy with rituximab in combination with standard chemotherapy has improved the survival of patients with advanced-stage follicular lymphoma (FL). A series of next-generation anti-CD20 antibodies may be less immunogenic and have even greater antitumor activity through augmented interactions with host effector mechanisms responsible for tumor cell kill. Additional approaches with patient-specific immunoglobulin idiotype vaccines; novel monoclonal antibodies binding to biologically active cell-surface antigen are also demonstrating early clinical activity. Antibodies targeting radioisotopes, toxins or drugs are also slowly entering clinical trials and practice. Last, allogeneic stem cell transplantation following reduced-intensity conditioning provides graft-versus-tumor immune responses that may be able to control FL and allow this risky but potentially curative treatment option to older patents or those with comorbidities.
Maloney
David G
DG
Fred Hutchinson Cancer Rsch. Ctr., 1100 Fairview Ave. N, D1-100, Seattle, WA 98109, USA. dmaloney@fhcrc.org
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D020350:Graft vs Tumor Effect; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000276:immunology / Q000473:pathology* / Q000601:surgery; D019653:Myeloablative Agonists / Q000627:therapeutic use; D000069283:Rituximab; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D019653:Myeloablative Agonists; D000069283:Rituximab